DE69841164D1 - Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung - Google Patents

Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung

Info

Publication number
DE69841164D1
DE69841164D1 DE69841164T DE69841164T DE69841164D1 DE 69841164 D1 DE69841164 D1 DE 69841164D1 DE 69841164 T DE69841164 T DE 69841164T DE 69841164 T DE69841164 T DE 69841164T DE 69841164 D1 DE69841164 D1 DE 69841164D1
Authority
DE
Germany
Prior art keywords
sphingosine
polynucleotides
kits
phosphate lyase
modulating agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841164T
Other languages
English (en)
Inventor
Julie D Saba
Jianhui Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital Oakland Research Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Childrens Hospital Oakland Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cincinnati Childrens Hospital Medical Center, Childrens Hospital Oakland Research Center filed Critical Cincinnati Childrens Hospital Medical Center
Application granted granted Critical
Publication of DE69841164D1 publication Critical patent/DE69841164D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Cosmetics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Detergent Compositions (AREA)
DE69841164T 1997-09-29 1998-09-29 Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung Expired - Lifetime DE69841164D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/939,309 US6423527B1 (en) 1997-09-29 1997-09-29 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
PCT/US1998/020365 WO1999016888A2 (en) 1997-09-29 1998-09-29 Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor

Publications (1)

Publication Number Publication Date
DE69841164D1 true DE69841164D1 (de) 2009-10-29

Family

ID=25472928

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841164T Expired - Lifetime DE69841164D1 (de) 1997-09-29 1998-09-29 Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung

Country Status (9)

Country Link
US (8) US6423527B1 (de)
EP (1) EP1027443B1 (de)
JP (1) JP2001518303A (de)
AT (1) ATE443147T1 (de)
AU (1) AU9779498A (de)
CA (1) CA2305686A1 (de)
DE (1) DE69841164D1 (de)
HK (1) HK1030018A1 (de)
WO (1) WO1999016888A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
US6830881B2 (en) 1997-09-29 2004-12-14 Children's Hospital & Research Institute At Oakland Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
JP2002501751A (ja) * 1998-01-29 2002-01-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
EP1363643A2 (de) * 2000-12-22 2003-11-26 Medlyte, Inc. Zusammensetzungen und methoden zur behandlung und vorbeugung von kardiovaskulären erkrankungen und zur identifizierung therapeutischer mittel
US6692960B2 (en) * 2001-09-28 2004-02-17 Isis Pharmaceuticals, Inc. Antisense modulation of sphingosine-1-phosphate lyase expression
WO2003062390A2 (en) * 2002-01-17 2003-07-31 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
US7674580B2 (en) * 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
US20040126834A1 (en) * 2002-01-17 2004-07-01 Children's Hospital And Research Institute At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
ES2749400T3 (es) * 2003-06-06 2020-03-20 Univ Texas Soluciones de purgado antimicrobianas
WO2005050222A1 (en) * 2003-11-19 2005-06-02 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of the human sgpl1 gene and protein for neurodegenerative diseases
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
PT1812797E (pt) * 2004-10-28 2013-05-21 Lpath Inc Composições e métodos para o tratamento e prevenção de doenças hiperproliferativas
WO2006135862A2 (en) * 2005-06-10 2006-12-21 Children's Hospital And Research Center At Oakland Immunomodulation by altering sphingosine 1-phosphate lyase (spl) activity
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US20080138334A1 (en) * 2006-05-31 2008-06-12 Sabbadini Roger A Immune-Derived Moieties Reactive Against Bioactive Lipids, and Methods of Making and Using Same
US9274129B2 (en) * 2006-05-31 2016-03-01 Lpath, Inc. Methods and reagents for detecting bioactive lipids
US8796429B2 (en) * 2006-05-31 2014-08-05 Lpath, Inc. Bioactive lipid derivatives, and methods of making and using same
US9274130B2 (en) 2006-05-31 2016-03-01 Lpath, Inc. Prevention and treatment of pain using antibodies to lysophosphatidic acid
US7862812B2 (en) 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
CA2667706A1 (en) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
RU2460541C2 (ru) 2006-10-27 2012-09-10 Лпат, Инк. Композиции и способы связывания сфингозин-1-фосфата
US20080248032A1 (en) * 2006-11-21 2008-10-09 Children's Hospital & Research Center At Oakland Compositions and methods for protection against cardiac and/or central nervous system tissue injury by inhibiting sphingosine-1-phosphate lyase
TW200848029A (en) 2007-03-01 2008-12-16 Lexicon Pharmaceuticals Inc Heterocyclic compounds, compositions comprising them and methods of their use
TW200920355A (en) * 2007-09-06 2009-05-16 Lexicon Pharmaceuticals Inc Compositions and methods for treating immunological and inflammatory diseases and disorders
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
US9200309B2 (en) 2010-06-28 2015-12-01 Daiichi Sankyo Company, Limited Method for screening for S1P lyase inhibitors using cultured cells
US20130259851A1 (en) 2010-12-01 2013-10-03 Universitat Zurich Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases
US9120835B2 (en) 2011-06-28 2015-09-01 Daiichi Sankyo Company Limited Phosphoric acid ester derivatives
EP3443986A1 (de) * 2017-08-17 2019-02-20 AC BioScience Verbesserung des chemotherapiewirkungsgrades durch sphingosin-1-phosphat

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260288A (en) 1992-04-03 1993-11-09 The Biomembrane Institute Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives
US5376531A (en) * 1992-09-03 1994-12-27 Northwestern University Method of detecting cancer
US5430169A (en) 1994-02-14 1995-07-04 The United States Of America Represented By The Department Of Health And Human Services Method for preparation of sphingoid bases
US6830881B2 (en) 1997-09-29 2004-12-14 Children's Hospital & Research Institute At Oakland Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
US6423527B1 (en) 1997-09-29 2002-07-23 Children's Hospital Medical Center Of Northern California Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
JP2002501751A (ja) * 1998-01-29 2002-01-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
WO1999061581A2 (en) 1998-05-26 1999-12-02 Office Of The Dean Of Research And Graduate Education Sphingosine kinase, cloning, expression and methods of use
WO2000070028A1 (en) 1999-05-13 2000-11-23 Johnson & Johnson Research Pty. Limited Sphingosine kinase enzyme
AU1020201A (en) 1999-10-28 2001-05-08 Warner-Lambert Company Human sphingosine kinase gene
WO2001042479A2 (en) 1999-12-08 2001-06-14 Genoptera, Llc Insecticide targets and methods of use
AU2153401A (en) 1999-12-29 2001-07-16 Aros Applied Biotechnology Aps Gene expression in biological conditions
AU2001238283C1 (en) 2000-02-14 2006-02-02 Curagen Corporation Sphingosine kinases
AUPQ744700A0 (en) 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
WO2002027028A1 (en) 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
WO2002059376A1 (en) 2001-01-23 2002-08-01 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of human colon cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
WO2002085298A2 (en) 2001-04-20 2002-10-31 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
US7189507B2 (en) 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20060252035A1 (en) 2001-08-06 2006-11-09 Lori Friedman Sphks as modifiers of the p53 pathway and methods of use
US7674580B2 (en) 2002-01-17 2010-03-09 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
WO2003062390A2 (en) 2002-01-17 2003-07-31 Children's Hospital & Research Center At Oakland Compositions and methods for the modulation of sphingolipid metabolism and/or signaling

Also Published As

Publication number Publication date
US20030059922A1 (en) 2003-03-27
US20080085995A1 (en) 2008-04-10
WO1999016888A3 (en) 1999-06-24
CA2305686A1 (en) 1999-04-08
EP1027443B1 (de) 2009-09-16
ATE443147T1 (de) 2009-10-15
US7973143B2 (en) 2011-07-05
US6495359B1 (en) 2002-12-17
US7041291B2 (en) 2006-05-09
EP1027443A2 (de) 2000-08-16
AU9779498A (en) 1999-04-23
US7262044B2 (en) 2007-08-28
US6569666B1 (en) 2003-05-27
US20050221346A1 (en) 2005-10-06
HK1030018A1 (en) 2001-04-20
US6423527B1 (en) 2002-07-23
WO1999016888A2 (en) 1999-04-08
US20090203044A1 (en) 2009-08-13
JP2001518303A (ja) 2001-10-16
US20030166897A1 (en) 2003-09-04

Similar Documents

Publication Publication Date Title
DE69841164D1 (de) Sphingosin-1-phosphat-lyase polypeptide, polynukleotide und modulierende mitteln, und verfahren zu deren verwendung
Bielack et al. Advances in the management of osteosarcoma
DE69737684D1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
DE69632681D1 (de) Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren
DK2289A (da) Monoklonale antistoffer samt deres fremstilling og anvendelse
DE69738868D1 (de) Odieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
NO980002L (no) Kaskadepolymerkomplekser, fremgangsmåte for fremstilling, samt farmasöytiske midler inneholdende disse
DE69837529D1 (de) Proteinmarker für lungenkrebs und deren verwendung
HK1026739A1 (en) Methods for detecting cell apoptosis
DE69510336D1 (de) Verfahren zur diagnose von praeklampsie
ATE175996T1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
ATE350662T1 (de) Markerproteine für prostatakrebs
DE69821246D1 (de) Testverfahren für collagenpeptid
DE69734894D1 (de) Testverfahren für antifibrotischen wirkstoff
DE69839876D1 (de) Prostat-spezifisches-antigenformen und verfahren zu ihrer bestimmung
DE69825629D1 (de) Säugertier edg-7 rezeptor homologen
ATE196688T1 (de) Verfahren zur vorhersage der therapeutischen antwort eines medikamentes auf einen malignen tumoren
DE69209063D1 (de) Vorprüfung von prostatakrebs durch serum prostatischen spezifischen antigen
WO2003062390A3 (en) Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
Chitapanarux et al. C-type natriuretic peptide induces human colonic myofibroblast relaxation
DK1100913T3 (da) MEKK 1 serin threonin kinaser - interagerende, FHA forkhead associeret domæneprotein 1 (MIF 1)
DE59708783D1 (de) Diagnosehilfe sowie verfahren zum nachweis der trächtigkeit von wiederkäuern
DE69815661D1 (de) Diagnostische verfahren und zusammensetzungen auf basis der verteilung von rad51

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLA, US

8364 No opposition during term of opposition